Health · World
US FDA Approves Lilly's Mounjaro for Cardiovascular Risk Reduction
The U.S. Food and Drug Administration (FDA) has approved Eli Lilly's drug Mounjaro (tirzepatide) for a new indication: to reduce the risk of cardiovascular events. This approval is specifically for individuals with type 2 diabetes who also have established cardiovascular disease. The drug, previously known for its use in managing type 2 diabetes and weight loss, will now be marketed for its cardiovascular benefits.
How outlets across the spectrum covered it
L 0 C 5 R 0
- Centre (5): Bloomberg, Reuters, TIME, The Wall Street Journal, USA Today